
Link to official URL (if available):
http://dx.doi.org/10.1136/bmj.g1490

(C) 2014, BMJ Publishing Group. Published in: Moore, A, Wiffen, P, Eccleston, C, Lunn, M, Hughes, R, Williams, A, Aldington, D & Kalso, E 2014, 'Andrew Moore and colleagues reply to Des Spence' BMJ, vol 348, g1490. Published version available via:
http://dx.doi.org/10.1136/bmj.g1490

Opus: University of Bath Online Publication Store
http://opus.bath.ac.uk/

This version is made available in accordance with publisher policies. Please cite only the published version using the reference above.

See http://opus.bath.ac.uk/ for usage policies.

Please scroll down to view the document.
Andrew Moore and colleagues reply to Des Spence

Andrew Moore *honorary senior research fellow*, Phil Wiffen *honorary professor*, Christopher Eccleston *professor*, Michael Lunn *consultant neurologist*, Richard Hughes *honorary professor*, Amanda Williams *clinical reader*, Dominic Aldington *consultant anaesthetist, consultant in pain management*, Eija Kalso *professor*

1Pain Research and Nuffield Division of Anaesthetics, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 7LE, UK; 2Centre for Pain Research, University of Bath, Bath, UK; 3National Hospital for Neurology and Neurosurgery and MRC Centre for Neuromuscular Diseases, London, UK; 4Research Department of Clinical, Educational, and Health Psychology, University College London, London, UK; 5Royal Hampshire County Hospital, Winchester, UK; 6Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki and Pain Clinic, Department of Anaesthesia and Intensive Care Medicine, Helsinki University Central Hospital, Helsinki, Finland

Spence’s polemic on duloxetine loses power because most of what it is based on is wrong.1 Making pronouncements in respected journals about good and bad medicine comes with the responsibility of knowing what you are talking about. Bad scholarship helps no one, especially those in pain; research in genetics, neurobiology, and psychology has contributed to huge advances in knowledge about the bio-psycho-social origins of pain.

Chronic pain is defined as pain of moderate or severe intensity that lasts for three months or more (think of a really bad headache lasting from Christmas to Easter). It affects one in five adults. Painful conditions are among the most prevalent conditions and are five of the top 11 in terms of years living with disability. Chronic pain destroys lives, has a huge negative impact on quality of life, is costly, reduces the ability to work or function inside the family, and may be associated with decreased life expectancy.

Here is a brief, non-comprehensive list of where Spence misses the point.

Women are not over-represented in trials. Chronic pain disproportionately affects women; their representation matches the epidemiology.

Pain is the most immediate of patient outcome measures, reported by patients themselves. Its subjectivity was recognised in the 1950s and dealt with. Different scales show excellent agreement, and patients in clinical trials record consistent pain levels over long periods, as in clinical practice.

Average benefits over placebo are in the order of 1 point on a 10 point rating score. But few patients are average; most have either little or great benefit. A responder is defined as someone with at least a 50% reduction in pain intensity maintained for 12 weeks, without intolerable adverse events that mean stopping treatment. Patients want this outcome, and it is accompanied by major improvements in sleep, function, and quality of life.

Cochrane reviews do not report effective non-drug alternatives. One of exercise in fibromyalgia involved only 223 patients in four small trials of barely adequate quality; another of psychological therapies found that effects are at best weak and that more research is urgently needed.2 Cochrane reviews endorse nothing.3 Several large good quality trials provide good evidence that duloxetine is effective in painful diabetic neuropathy and fibromyalgia. The effect size is not massive—a number needed to treat of five tells you that—but it is comparable to other treatments in neuropathic and other chronic pain, where treatment failure is expected more often than treatment success.4

We are not “steeped in conflicts of interest.” Some (but not all) make declarations of interest, not quite the same as conflicts. We are proud of this, when it means bringing otherwise unpublished information into the public domain, accessing data at the level of the individual patient to improve understanding of evidence and outcomes, and, importantly, demonstrating new sources of large potential bias. Our rule over 30 years is that we work only with organisations that agree an unrestricted right to publish the results, whatever they may be.

Spence omits the most important, valid, criticisms. These might include the bias against older treatments because authorities require trials fundable only by industry or government (which neither fund). Effective drugs like amitriptyline are understudied so have less evidence of efficacy to support their use. In addition, inappropriate imputation methods in statistical analysis

* BMJ 2014;348:g1490 doi: 10.1136/bmj.g1490 (Published 19 February 2014)
of results can mean that efficacy is sometimes hugely inflated; this is not the case for duloxetine.\(^6\)

Patients need options. Encouraging people to act against the evidence is the real “bad medicine.”

Competing interests: ML, RH, and PW wrote a Cochrane review on duloxetine. AM has received honorariums for consulting from Eli Lilly. AM, DA, and EK were authors of a BMJ article criticised by Spence. CE and AW declare no conflicts.

Full response at: www.bmj.com/content/348/bmj.g139/rr/685335.

Cite this as: BMJ 2014;348:g1490

© BMJ Publishing Group Ltd 2014

1 Spence D. Bad medicine: the rise of duloxetine. BMJ 2014;348:g139. (17 January.)